Amgen (AMGN): Kyprolis Fails to Show PFS Benefit - BMO

September 27, 2016 9:10 AM EDT
Get Alerts AMGN Hot Sheet
Price: $158.51 -1.85%

Rating Summary:
    17 Buy, 14 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade AMGN Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

BMO Capital analyst, Ian Somaiya, reiterated his Outperform rating on shares of Amgen (NASDAQ: AMGN) after Kyprolis failed to show a PFS benefit versus Velcade in front-line myeloma.

These results do not impact the analyst's estimates but they do eliminate ~ $1.5bn in potential upside.

Kyprolis now faces increased risk from generic Velcade as positive data could reduce pressure from payors to switch to generic. The majority of impact will be in Europe as melphalan/prednisone regimens have limited (<5%) US use.

No change to the price target of $190.

For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.

Shares of Amgen closed at $173.53 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

BMO Capital

Add Your Comment